Mark van der Laan, PhD

Professor
University of California, Berkeley, CA, USA; TL Revolution, Cambridge, MA, USA

Poster(s):

• (352) Transportability to the EU Population of the Efficacy of Belumosudil Versus Best Available Therapy for the Treatment of Chronic Graft-Versus-Host Disease
  Wednesday, October 29, 2025